Biocon Ltd. — Regulatory Filings 2021

Mar 19, 2021

==> picture [140 x 54] intentionally omitted <==

Biocon Limited 20th KM Hosur Road Electronics City Bangalore 560 100, India T 91 80 2808 2808 F 91 80 2852 3423

CIN : l24234KA 1978PLC003417

www.biocon.com

March 19, 2021

To	To
The Manager	The Manager,
BSE Limited	National Stock Exchange of India Limited
Department of Corporate Services	Corporate Communication Department
Phiroze Jeejeebhoy Towers,	Exchange Plaza, Bandra Kurla Complex,
Dalal Street,Mumbai - 400 001	Mumbai - 400 050
Scrip Code- 532523	Scrip Symbol- Biocon

Subject: Intimation for Incorporation of Wholly Owned Subsidiary Company

Dear Sir/ Madam,

With reference to the captioned subject, we would like to inform you that the Company has incorporated a wholly owned subsidiary company "Biofusion Therapeutics Limited" on March 18, 2021.

The details as required under SEBI Listing Regulations read with SEBI Circular No. CIR/CFO/CMD/4/2015 dated September 9, 2015 are as under: -

CIR/CFO/	CMD/4/2015 dated September 9, 2015 are as under: -
S. No.	Particulars	Details
1	Name of the target entity, details in brief such as size. turnover etc.	Biofusion Therapeutics Limited Share Capital (a) Authorised Share Capital: Rs. 15,00,000 /- (b) Paid-up Capital: Rs. 5,00,000/- Turnover: Nil (Yettocommence business operations)
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/groupcompanieshaveany interest in the entitybeingacquired? Ifyes,nature	NA

==> picture [72 x 79] intentionally omitted <==

==> picture [138 x 54] intentionally omitted <==

	of interest and details thereof and whether the same is done at "arm's length"
3	Industryto which the entitybeingacquired belongs;	Pharmaceutical
4	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	Thebusinessofwhollyowned subsidiary company would be in the field of Research and Development and allied services.
5	Brief details of any governmental or regulatory approvals required for the acquisition;	TheCorporateIdentityNumber ('CIN') of the Company is U73100KA2021PLC145487,issued by Ministry of Corporate Affairs, Government of India.
6	Indicativetimeperiod forcompletion of the acquisition;	NA
7	Nature of consideration ~~-~~ whether cash considerationor share swapand details of the same;	Cash
8	Cost of acquisition or the price at which the shares are acquired;	Rs. 5,00,000/- (50,000 equity shares of Rs. 10/- each)
9	Percentage of shareholding/ control acquired and/ or number of shares acquired;	100%
10	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and anyother significant information(in brief);	Biofusion Therapeutics Limited is i nco rpo ratedwith Registrarof Companies, Bengaluru, Karnataka, on March 18, 2021 and is yet to commence its business operations.

The above information will also be available on the website of the Company at www.biocon.com.

Kindly take the same on record and acknowledge.

Thanking You, For Biocon Limited

==> picture [68 x 30] intentionally omitted <==

==> picture [81 x 79] intentionally omitted <==

Mayank Verma Company Secretary and Compliance Officer